Latest news with #RecorMedical
Yahoo
17-05-2025
- Health
- Yahoo
Innovations in High Blood Pressure Intervention Benefit Patients with Resistant Hypertension
World Hypertension Day's focus on High Blood Pressure Awareness, Management and Control highlights Importance of New Therapies, like Ultrasound Renal Denervation from Recor Medical PALO ALTO, Calif., FRANKFURT, Germany, May 17, 2025 /PRNewswire/ -- May 17, 2025, is World Hypertension Day, a day dedicated to raising awareness about high blood pressure, also known as the "silent killer" because many people do not know they have it and, over time, it can lead to serious health issues. The theme of World Hypertension Day, "Measure Your Blood Pressure Accurately, Control It, Live Longer!" highlights the importance of not only awareness but also accurate monitoring, diagnosis, and treatment of hypertension. According to a report from the World Health Organization, the number of adults with hypertension doubled between 1990 and 2019 from 650 million to 1.3 billion. The report also states that only 54 percent of adults with hypertension are diagnosed and only 42 percent receive treatment. And recent studies1,2 have suggested that BP assessment in the clinical setting can often get a hypertension diagnosis wrong or miss it completely. Left undetected or uncontrolled, hypertension is a leading contributor to serious health risks, including heart attack, stroke and kidney disease, making accurate diagnosis, monitoring and treatment of the condition critical. About one-third of the patients who are treated for hypertension remain uncontrolled despite making healthy lifestyle changes and taking more than three medications. For these patients, innovation and investment in new solutions are vital to achieve blood pressure control and realize a healthier future. From pharmaceutical treatments to technology, patients need new therapies that can provide life-changing results. This includes medical device-based therapies, like the Paradise™ Ultrasound Renal Denervation (uRDN) system, an additional treatment option for patients who remain uncontrolled and at elevated cardiovascular risk despite standard lifestyle changes and treatment with oral medications. The Paradise uRDN system is a first-of-its-kind ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension. The Paradise uRDN system delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through the main renal arteries to the surrounding nerves.* The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall. This minimally invasive procedure is supported by many medical societies including the American Heart Association, the American College of Cardiology, the European Society of Cardiology and others. "Taking a risk-based approach to hypertension makes sense and this is why the medical societies are increasingly behind it," said Prof. Andrew Sharp, University College Dublin and The Mater Misericordiae Hospital, Dublin, Ireland. "Blood pressure reductions of just 5 to 10mmHg can have a significant impact on the risk of cardiovascular complications, such as stroke and heart attack, but gain is greatest in those who are most at risk, such as patients who also have other risk factors for cardiovascular health such as diabetes. Early blood pressure control may also limit the vascular aging process and yet over half of patients worldwide are not even at the basic standard of control of 140/90mmHg. With guidelines now suggesting lower BP targets of 130/80 for many, new treatments in this space are welcome. Renal denervation is a recently approved tool to safely aid in blood pressure lowering throughout the 24-hour cycle and is independent of patient adherence to medication. The procedure shows an excellent safety profile and typically takes under an hour to perform, with lasting BP reductions demonstrated." Recor Medical – the manufacturer of the Paradise System - has been focused on developing and testing uRDN for the treatment of hypertension since 2009, and completed three independently powered, sham-controlled, randomized clinical trials, all which demonstrate the efficacy and safety of the Paradise System. Recor has also initiated the US Global Paradise System (GPS) Post-Approval Study to collect real-world clinical evidence with long-term follow-up in 1,000 patients with uncontrolled hypertension in the United States. The Paradise uRDN system is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. A physician will make a medical assessment to determine if a patient is a candidate for ultrasound renal denervation. The most common risks include pain, vascular access site complications and vasospasm. Full important risk information can be viewed here. *Anatomies vary. See Paradise IFU for treatment strategies. Liu H et al.: Arm Position and Blood Pressure Readings. The ARMS Crossover Randomized Clinical Trial. JAMA Intern Med. 2024;184(12):1436-1442. doi:10.1001/jamainternmed.2024.5213 About Recor Medical, Medical, headquartered in Palo Alto, Calif., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension. Recor has pioneered the use of the Paradise Ultrasound Renal Denervation system for the treatment of hypertension. The Paradise uRDN system is an investigational device in Japan, is FDA approved in the United States, and bears the CE mark. Recor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise uRDN system in patients with mild-to-moderate and resistant hypertension. In addition, Recor is conducting the Global Paradise System ("GPS") Registry in the European Union and the UK, and has initiated the US GPS post-approval study in the United About Otsuka Medical Devices Co., Medical Devices Co., Ltd. engages in the global development and commercialization of medical devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices is a subsidiary of Otsuka Holdings Co., Ltd. ( a global healthcare company listed on the Tokyo Stock Exchange (JP 4578). Photo: View original content to download multimedia: SOURCE Recor Medical Inc.
Yahoo
16-05-2025
- Health
- Yahoo
A New Option for Treating High Blood Pressure is Available to United States Veterans
Ultrasound Renal Denervation, a Proven Treatment for High Blood Pressure, is Available to Veterans Thanks to a Partnership Between Recor Medical and Recon Supply ST. CHARLES, Mo., May 16, 2025 /PRNewswire/ -- Hypertension, or high blood pressure, is known as the "silent killer" because many people do not know they have it and, over time, it can lead to serious health issues. In fact, hypertension increases the risk of heart disease and stroke, two of the leading causes of death in the United States. The 2020 Veterans Health Administration (VHA) guidelines on hypertension define uncontrolled hypertension as a reading above or equal to 130/90 mmHg.1 66% of veterans diagnosed with hypertension are considered uncontrolled by the VHA's guidelines.2 Hypertension treatment typically begins with a change in diet, like reducing salt intake, and physical exercise. For some, medication may also be prescribed. However, about one-third of the patients who are treated for hypertension remain uncontrolled despite making healthy lifestyle changes and taking more than three medications. For these patients, medical device-based hypertension therapies, like the Paradise™ Ultrasound Renal Denervation (uRDN) system, may be an additional treatment option. Army veteran Richard Van Name is one such patient who was looking for another way to treat his uncontrolled hypertension. An Army pilot for more than 30 years, Richard noticed his blood pressure was increasing during the later part of his service, and he was diagnosed with hypertension after retirement. Despite adjusting his lifestyle and taking progressively more medications, his blood pressure had not reached a normal level. That's when his physician recommended that he consider the Paradise uRDN treatment, a one-time, safe and minimally invasive procedure that is clinically proven to reduce blood pressure.3-6 "My blood pressure was starting to creep up in the last part of my career, but they were still within the limits for the military. When I was first diagnosed with hypertension, my blood pressure was 178 over 100. Diet and exercise did not bring it down any, and the medication brought it down to around the 150 to 160 region," said Richard. "My cardiologist was not satisfied that the maximum he had prescribed had not brought it down to where he thought was best. The doctor prescribed ultrasound renal denervation, and the procedure had definite results. My wife and I feel a lot better because it relieves us of the chances of heart attack or stroke." The Paradise uRDN system is a first-of-its-kind ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension. The Paradise uRDN system delivers two to three doses of 360-degree ultrasound energy—lasting seven seconds each—through the main renal arteries to the surrounding nerves. The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall. This minimally invasive procedure is supported by many medical societies including the American Heart Association, the American College of Cardiology, the European Society of Cardiology and others. Recor Medical—the manufacturer of the Paradise System—has partnered with Service-Disabled Veteran Owned Small Business (SDVOSB) Recon Supply to support the distribution of the Paradise System through the VHA and Department of Defense. Recor has been focused on developing and testing uRDN for the treatment of hypertension since 2009, and completed three independently powered, sham-controlled, randomized clinical trials, all which demonstrate the efficacy and safety of the Paradise System, leading to FDA approval in late 2023. Recor has also initiated the US Global Paradise System (GPS) Post-Approval Study to collect real-world clinical evidence with long-term follow-up in 1,000 patients with uncontrolled hypertension in the United States. The Paradise uRDN system is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. A physician will make a medical assessment to determine if a patient is a candidate for ultrasound renal denervation. The most common risks include pain, vascular access site complications and vasospasm. Full important risk information can be viewed here. Defense DoVAaDo. VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension in the Primary Care Setting. 2020. Yamada et al. J Hypertens. 2023 Apr 17;41(6):995–1002. Azizi et al. JAMA. 2023;329(8):651-661. Azizi et al. Lancet. 2018 Jun 9;391(10137):2335-2345. Azizi et al. Lancet. 2021 Jun 26;397(10293):2476-2486. Kirtane et al. JAMA Cardiol. 2023;8(5):464-473. About Recon Supply Recon Supply is an SBA-certified Service-Disabled Veteran Owned Small Business (SDVOSB), demonstrating its commitment to serving the country both in and out of uniform. The company takes pride in its veteran-led team and its dedication to providing exceptional service to military and government clients. For more information on Recon Supply's offerings, visit or contact Recon Supply at 314-317-0300. About Recor Medical, Medical, headquartered in Palo Alto, Calif., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension. Recor has pioneered the use of the Paradise Ultrasound Renal Denervation system for the treatment of hypertension. The Paradise uRDN system is an investigational device in Japan, is FDA approved in the United States, and bears the CE mark. Recor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise uRDN system in patients with mild-to-moderate and resistant hypertension. In addition, Recor is conducting the Global Paradise System ("GPS") Registry in the European Union and the UK, and has initiated the US GPS post-approval study in the United States. Media Contact Katy ClarkEmail - Katy@ View original content to download multimedia: SOURCE Recon Supply
